Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

• Status: Terminated
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate increased graft versus leukemia (GVL) responses without causing graft-versus-host disease (GVHD).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Alemtuzumab; Fludarabine; Fludarabine phosphate; Melphalan

Criteria

Inclusion Criteria:

• Relapsed or refractory acute myelogenous or lymphoid leukemia.

• Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.

• Chronic myelogenous leukemia in accelerated phase or blast-crisis.

• Chronic myelogenous leukemia in second or subsequent chronic phase

• Recurrent or refractory malignant lymphoma or Hodgkin's disease

• Multiple myeloma at high risk for disease recurrence.

• Chronic lymphocytic leukemia, relapsed or with poor prognostic features.

• Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.

Exclusion Criteria:

• Clinical progression.

• Contra-indications for vaccination.